Protecting Health Care for All Patients Act · House · Feb 7, 2024 · 211–208
Ban cost-per-life-year drug pricing
Share voting the stated Pharma and health care position (yea)
51%
$10K+: 193 of 382 covered members
vs
49%
Below $10K: 18 of 37 covered members
Compare within each recorded party
Democrats: $10K+ 0% (0/189); below $10K 0% (0/19).
Republicans: $10K+ 100% (193/193); below $10K 100% (18/18).
Party comes from Voteview’s member record for the roll call’s Congress and may not capture changes within that Congress. Party splits do not adjust for tenure, committee roles or the mix of selected votes. Small groups can produce unstable percentages.
$198K
average traced funding, with industry; 211 covered members
$218K
average traced funding, against industry; 208 covered members
0
voting members excluded for unavailable coverage
$10K+, voted with industry
- Brett Guthrie$2.2M
- Jason Smith$1.3M
- John Joyce$1.2M
- Richard Hudson$1.2M
- Gus Bilirakis$1.1M
$10K+, voted against industry
- Frank Pallone$1.6M
- Richard Neal$1.5M
- Raul Ruiz$1.2M
- Terri Sewell$1.1M
- Scott Peters$1.1M
Barred federal programmes from using quality-adjusted life years to decide what a drug is worth, which drug makers see as the gateway to price controls. Passed 211–208. This is a retrospective comparison. Funding includes covered 2020–2026 election cycles and may have arrived after the vote. It does not measure whether money changed a vote. 0 voting members excluded for unavailable coverage. Threshold: $10K in traced funding.
The full detail →